TY - JOUR T1 - Mortality from COVID in Colombia and Peru: Analyses of Mortality Data and Statistical Forecasts JF - medRxiv DO - 10.1101/2020.08.24.20181016 SP - 2020.08.24.20181016 AU - Patrick E Brown AU - Zoƫ R Greenwald AU - Luis Ernesto Salinas AU - Gabriel Aguirre Martens AU - Leslie Newcombe AU - Hellen Gelband AU - Jeremy Veillard AU - Prabhat Jha Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/16/2020.08.24.20181016.abstract N2 - National predictions of the course of COVID mortality can be used to plan for effective healthcare responses as well as to support COVID policymaking. We developed the Global COVID Assessment of Mortality (GCAM), a statistical model with continually improving precision that combines actual mortality counts with Bayesian inference, to predict COVID trends, currently until December 1, 2020. In Colombia, the GCAM analysis found the peak of COVID mortality around August 12 and an expected total of COVID deaths of 24,000-31,000, or 48%-92% over the total through August 21. In Peru, a first mortality peak occurred around May 24, and given the current trajectory, a second peak is predicted around September 6. Peru can expect 29,000-43,000 COVID deaths, representing an increase of 7%-55% over COVID deaths through August 21. GCAM projections are also used to estimate medical surge capacity needs. To gauge the reliability of COVID mortality forecasts, we compared all-cause mortality from January through June 2020 with average all-cause mortality in previous years in Colombia and Peru, and found that the excesses were consistent with GCAM forecast, most notably a doubling of overall mortality from May 25-June 7th of weeks in Peru. The GCAM results predict that as a percentage of all adult deaths in previous years, Colombia can expect about 13% excess from COVID deaths, whereas Peru can expect 34% excess. Comparisons of GCAM analyses of several other countries with Colombia and Peru demonstrate the extreme variability that characterizes COVID mortality around the world, emphasizing the need for country-specific analyses and ongoing monitoring as more mortality data become available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the World Bank, the Canadian Institutes of Health Research Foundation grant (FDN 154277) and Emergency COVID Research Grant, the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-06856) and the Connaught Global Challenge program of the University of Toronto. Prabhat Jha is a Canada Research Chair and Dalla Lana Chair of Global Health at the University of Toronto. The funders had no role in the study design, conduct, and reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval from the IRB was not required as all data are publicly available and no individual patient data were used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the GCAM model were taken from publicly available sources (as cited). The GCAM statistical forecasts are updated regularly and made available at http://www.cghr.org/covid. ER -